News | February 06, 2025
JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Subscribe To Our Newsletter & Stay Updated
